Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Novel protocol for the transcriptomic analysis of endothelial extracellular vesicles in atherosclerosis, Nuevo protocolo para el análisis transcriptómico de las vesículas extracelulares endoteliales en aterosclerosis

  • Saenz-Pipaon, Goren
  • Cenarro, Ana
  • Zazpe, Jon
  • Goñi Olóriz, Miriam
  • Martínez Aguilar, Esther
  • Machado, Florencio J.D.
  • Marchese, Francesco P.
  • Orbe, Josune
  • López Andrés, Natalia
  • Civeira, Fernando
  • Páramo, José A.
  • Lara-Astiaso, David
  • Roncal Mancho, Carmen
Introduction: Despite the key role of the endothelium in atherosclerosis, there are no direct techniques for its analysis. The study of extracellular vesicles of endothelial origin (EEVs), might lead to the identification of molecular signatures and early biomarkers of atherosclerosis. The aim of this work was to set up the methods for EEVs separation and transcriptomic analysis. Methods: We adapted an antibody-magnetic-bead based immunocapture protocol for plasma EEVs separation from control (G1), subclinical atherosclerosis (G2) and peripheral artery disease subjects (PAD) (G3), and modified an ultra-low input RNASeq method (n = 5/group). By bioinformatics analysis we compared the transcriptome of plasma EEVs with that of human aortic endothelial cells (TeloHAECs), and then, searched for differentially expressed genes (DEG) among EEVs of G1, G2 and G3. From those DEG, UCP2 was selected for further validation in plasma EVs (qPCR), and in vitro, in stimulated TeloHAECs (IL-1 beta, TNF alpha, oxLDL and hypoxia). Results: The RNASeq analysis of plasma EEVs rendered 1667 genes enriched in transcripts expressed by TeloHAECs (NES: 1.93, p adjust = 1.4(e-73)). One hundred seventy DEGs were identified between G2 vs G1, and 180 between G3 vs G1, of which 17 were similarly expressed in G2 and G3 vs control, including UCP2. IL-1 beta and TNF alpha (10 ng/mL, p < 0.05), hypoxia (1% O-2, p = 0.05) and oxLDL (100 mu g/mL, p = 0.055) reduced UCP2 expression in TeloHAECs. Conclusions: We set up a protocol for EEVs separation and sequencing that might be useful for the identification of early markers of endothelial dysfunction in atherosclerosis., The Foundation for Applied Medical Research, Universidad de Navarra (Spain) ; Sociedad Espanola de Arteriosclerosis (Beca FEA/SEA 2019 - Clinico Epidemiologica I) ; Project PI21/00622, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. The 8-2021 project has received 50% co-financed aid from the European Regional Development Fund through the ERDF 2014-2020 Operational Program of Navarra. This research was supported by CIBER - Consorcio Centro de Investigacion Biomedica en Red -Cardiovascular (CB16/11/00483 and CB16/11/00451), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Extracellular vesicles in atherosclerosis: current and forthcoming impact, Vesículas extracelulares en aterosclerosis: impacto actual y futuro

  • Páramo, José A.
  • Cenarro, Ana
  • Civeira, Fernando
  • Roncal Mancho, Carmen
La aterosclerosis es el principal sustrato patogénico de las enfermedades cardiovasculares (ECV). Considerada inicialmente como un depósito pasivo de colesterol, hoy se asume que es un proceso activo, donde la inflamación juega un papel clave en su inicio y progresión. A pesar de los avances realizados, los pacientes con ECV presentan alto riesgo de episodios trombóticos y elevada mortalidad, por lo que sigue siendo necesario profundizar en los mecanismos de la aterogénesis e identificar nuevos biomarcadores diagnósticos y pronósticos para estratificar el riesgo. En este sentido, se ha postulado que las vesículas extracelulares (EV) podrían representar nuevos biomarcadores de la enfermedad aterosclerótica, siendo de interés investigar su participación en la comunicación intercelular que favorece el remodelado arterial. Las EV son partículas lipídicas liberadas por numerosas células en condiciones fisiológicas y patológicas, que contienen lípidos, proteínas y ácidos nucleicos procedentes de las células parentales. Consideradas inicialmente como material de desecho, hoy se sabe que son efectores activos de numerosos procesos celulares, constituyendo biomarcadores potenciales con significado diagnóstico y pronóstico en la ECV. En esta revisión se sintetiza el papel de las EV como biomarcadores potenciales de las ECV y su participación en procesos que favorecen la aterosclerosis., Atherosclerosis is the main pathogenic substrate for cardiovascular diseases (CVDs). Initially categorized as a passive cholesterol storage disease, nowadays, it is considered an active process, identifying inflammation among the key players for its initiation and progression. Despite these advances, patients with CVDs are still at high risk of thrombotic events and death, urging to deepen into the molecular mechanisms underlying atherogenesis, and to identify novel diagnosis and prognosis biomarkers for their stratification. In this context, extracellular vesicles (EVs) have been postulated as an alternative in search of novel biomarkers in atherosclerotic diseases, as well as to investigate the crosstalk between the cells participating in the processes leading to arterial remodelling. EVs are nanosized lipidic particles released by most cell types in physiological and pathological conditions, that enclose lipids, proteins, and nucleic acids from parental cells reflecting their activation status. First considered cellular waste disposal systems, at present, EVs have been recognized as active effectors in a myriad of cellular processes, and as potential diagnosis and prognosis biomarkers also in CVDs. This review summarizes the role of EVs as potential biomarkers of CVDs, and their involvement into the processes leading to atherosclerosis., The Foundation for Applied Medical Research, Universidad de Navarra (Spain); the Ministry of Science and Innovation, Institute of Health Carlos III, co-funded by the European Fund for Economic and Regional Development (FEDER) [PI21/00622, Gobierno de Navarra 8-2021]. The 8-2021 project has received 50% co-financed aid from the European Regional Development Fund through the ERDF 2014-2020 Operational Program of Navarra. This research was supported by CIBER --- Consorcio Centro de Investigación Biomédica en Red --- Cardiovascular (CB16/11/00483 and CB16/11/00451), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Novel protocol for the transcriptomic analysis of endothelial extracellular vesicles in atherosclerosis

  • Saenz-Pipaon, Goren
  • Cenarro, Ana
  • Zazpe, Jon
  • Goñi-Oloriz, Miriam
  • Martinez-Aguilar, Esther
  • Machado, Florencio J.D.
  • Marchese, Francesco P.
  • Orbe, Josune
  • López-Andrés, Natalia
  • Civeira, Fernando
  • Paramo, Jose A.
  • Lara-Astiaso, David
  • Roncal, Carmen
Introduction: Despite the key role of the endothelium in atherosclerosis, there are no direct techniques for its analysis. The study of extracellular vesicles of endothelial origin (EEVs), might lead to the identification of molecular signatures and early biomarkers of atherosclerosis. The aim of this work was to set up the methods for EEVs separation and transcriptomic analysis. Methods: We adapted an antibody-magnetic-bead based immunocapture protocol for plasma EEVs separation from control (G1), subclinical atherosclerosis (G2) and peripheral artery disease subjects (PAD) (G3), and modified an ultra-low input RNASeq method (n = 5/group). By bioinformatics analysis we compared the transcriptome of plasma EEVs with that of human aortic endothelial cells (TeloHAECs), and then, searched for differentially expressed genes (DEG) among EEVs of G1, G2 and G3. From those DEG, UCP2 was selected for further validation in plasma EVs (qPCR), and in vitro, in stimulated TeloHAECs (IL-1β, TNFα, oxLDL and hypoxia). Results: The RNASeq analysis of plasma EEVs rendered 1667 genes enriched in transcripts expressed by TeloHAECs (NES: 1.93, p adjust = 1.4e−73). One hundred seventy DEGs were identified between G2 vs G1, and 180 between G3 vs G1, of which 17 were similarly expressed in G2 and G3 vs control, including UCP2. IL-1β and TNFα (10 ng/mL, p < 0.05), hypoxia (1% O2, p = 0.05) and oxLDL (100 μg/mL, p = 0.055) reduced UCP2 expression in TeloHAECs. Conclusions: We set up a protocol for EEVs separation and sequencing that might be useful for the identification of early markers of endothelial dysfunction in atherosclerosis. Introducción: A pesar del papel clave del endotelio en la aterosclerosis, no existen técnicas directas para su análisis. El estudio de las vesículas extracelulares de origen endotelial (EEV) podría facilitar la identificación de firmas moleculares y biomarcadores tempranos de aterosclerosis. El objetivo de este trabajo fue establecer los métodos para la separación de EEV y su análisis transcriptómico. Métodos: Adaptamos un protocolo de inmunocaptura con anticuerpos y microesferas magnéticas para la separación de las EEV del plasma de sujetos control (G1), con aterosclerosis subclínica (G2) y con enfermedad arterial periférica (G3), y modificamos un método de RNASeq para su análisis transcriptómico (n = 5/grupo). Comparamos el transcriptoma de las EEV plasmáticas con el de células endoteliales de aorta humana (TeloHAEC) e identificamos genes diferencialmente expresados (DEG) entre los grupos de pacientes, incluyendo UCP2, validado en EV plasmáticas (qPCR) e in vitro, en TeloHAECs tratadas con IL-1β, TNF-α, oxLDL e hipoxia. Resultados: El RNASeq de las EEV plasmáticas detectó 1.667 genes enriquecidos en transcritos expresados por las TeloHAECs (NES: 1,93, ajuste p = 1,4e−73). Se identificaron 170 DEG entre los grupos G2 vs. G1 y 180 entre G3 vs. G1, de los cuales 17 se expresaron de forma similar en G2 y G3 vs. control, incluyendo UCP2. El tratamiento con IL-1β y TNF-α (10 ng/ml, p < 0,05), hipoxia (1% O2, p = 0,05) y oxLDL (100 μg/ml, p = 0,055) redujo la expresión de UCP2 en las TeloHAEC. Conclusiones: Hemos puesto a punto un protocolo para la separación y la secuenciación de EEV que podría ser útil para la identificación de marcadores tempranos de disfunción endotelial en aterosclerosis.